Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6352388 | 0.91 | ALB (0.51) | SIRT2SMN1; SMN2LMNAPOLBMEN1 | |
| SCHEMBL6352026 | 0.90 | SIRT2 (0.51) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6349541 | 0.90 | SIRT2 (0.51) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6357891 | 0.84 | APEX1 (0.51) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6353074 | 0.83 | APEX1 (0.49) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6352310 | 0.82 | APEX1 (0.52) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6820409 | 0.82 | MEN1 (0.46) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6822224 | 0.81 | ALB (0.38) | SIRT2MEN1KMT2AALB | |
| SCHEMBL6353732 | 0.81 | APEX1 (0.57) | SIRT2APEX1SMN1; SMN2LMNAPOLB | |
| SCHEMBL6350777 | 0.80 | SIRT2 (0.56) | SIRT2APEX1SMN1; SMN2LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | PHARMACIA & UPJOHN COMPANY | 2005-05-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113450-A1 | Antibacterial agents | CLPP, SPOUT1, SAMHD1 | SIRT2 3380/4885APEX1 502/4885SMN1; SMN2 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.